Key result
High hs-CRP/SA ratio is linked to ~6.5-fold higher major cardiovascular events risk in chronic heart failure outpatients.
Why the study?
The hs-CRP/SA ratio is emerging as a potential biomarker for cardiovascular risk stratification in CHF, but its long-term prognostic value for MACEs needed evaluation.
Does an elevated hs-CRP/SA ratio (≥ 1.19) predict an increased risk of major adverse cardiovascular events (MACEs) in outpatients with chronic heart failure?
Cohort (n=500)
No
Does an elevated hs-CRP/SA ratio (≥ 1.19) predict an increased risk of major adverse cardiovascular events (MACEs) in outpatients with chronic heart failure?
Answers are grounded in this paper and cite their sources.
An elevated hs-CRP to serum albumin ratio (≥ 1.19) is a strong, independent predictor of long-term major adverse cardiovascular events across all ejection fraction phenotypes in outpatients with chronic heart failure.
The ratio of high-sensitivity C-reactive protein (hs-CRP) to Serum albumin (SA) (hs-CRP/SA) is emerging as a new potential biomarker capable of stratifying cardiovascular risk in patients with chronic HF (CHF), particularly the risk of major adverse cardiovascular events (MACEs). Objectives: The aim of this study was to evaluate the long-term prognostic value of the hs-CRP/SA ratio on the risk of MACEs in a population of outpatients with CHF. Methods: In this retrospective observational study, 500 patients were enrolled and were stratified into two groups based on the median value of the hs-CRP/SA ratio: 249 patients with hs-CRP/SA < 1.19 and 251 patients with hs-CRP/SA ≥ 1.19. Results: During median follow-up of 5.2 years, 3.6 MACEs/100 patients/year were detected; patients with hs-CRP/SA ≥ 1.19 had a MACE incidence of 5.9 events per 100 patient-years, compared with 1.2 events per 100 patient-years in those with hs-CRP/AS < 1.19 (p < 0.001). Multivariate analysis confirmed that hs-CRP/SA ≥ 1.19 was associated with an approximately 6.5-fold increased risk of new MACEs (HR 6.513, 95% CI 3.928–10.797; p < 0.001). Conclusions: The hs-CRP/SA ratio is confirmed as a powerful prognostic marker in patients with CHF, associated with a significantly increased risk of MACEs.
No takes yet. Share an insight, caveat, or question.
Martire et al. (2026) conducted a cohort in Chronic heart failure (NYHA class II-III) (n=500). High-sensitivity C-reactive protein to serum albumin ratio (hs-CRP/SA) ≥ 1.19 vs. hs-CRP/SA ratio < 1.19 was evaluated on Major adverse cardiovascular events (MACEs: nonfatal myocardial infarction, nonfatal ischemic stroke, coronary revascularization [PCI or CABG], or cardiovascular death) (HR 6.513, 95% CI 3.928–10.797, p=< 0.001). An hs-CRP/SA ratio ≥ 1.19 was independently associated with a 6.5-fold increased risk of major cardiovascular events in chronic heart failure outpatients.
Synapse has enriched 10 related papers. Consider them for comparative context: